Jazz Pharmaceuticals (JAZZ)

• Market cap: $7.53B
• 1 day: 0.68%
• 5 days: 2.01%
• 1 month: 1.45%
• 3 months: 13.05%
• 6 months: 16.25%
• Year to date: -1.86%
• 1 year: 2.95%
• 5 years: -18.38%
• 10 years: -25.21%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Employees: 2,800

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

82% more call options, than puts

Call options by funds: $28.9M | Put options by funds: $15.9M

50% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 9 (+3) [Q3]

38% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 56

5% more funds holding

Funds holding: 447 [Q2] → 468 (+21) [Q3]

1.13% more ownership

Funds ownership: 92.27% [Q2] → 93.4% (+1.13%) [Q3]

3% more capital invested

Capital invested by funds: $6.21B [Q2] → $6.42B (+$207M) [Q3]

3% more repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 156

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $162 30% upside
• Avg. target: $184 48% upside
• High target: $207 66% upside

6 analyst ratings

• positive: 6 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler David Amsellem 51% 1-year accuracy 19 / 37 met price target	31% upside $163	Overweight Reiterated	12 Dec 2024
RBC Capital Gregory Renza 38% 1-year accuracy 31 / 82 met price target	44% upside $179	Outperform Reiterated	12 Dec 2024
Needham Ami Fadia 35% 1-year accuracy 54 / 154 met price target	66% upside $207	Buy Reiterated	12 Dec 2024
HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 23 / 46 met price target	61% upside $200	Buy Reiterated	22 Nov 2024
Baird Joel Beatty 48% 1-year accuracy 21 / 44 met price target	30% upside $162	Outperform Maintained	18 Nov 2024